Alyeska Investment Group L.P. Makes New Investment in Elanco Animal Health Incorporated $ELAN

Key Points

• Alyeska Investment Group acquired 1.5 million Elanco Animal Health shares worth approximately $36.9 million, while institutional investors collectively own 97.48% of the company.
• Analysts maintain a generally positive outlook, with Elanco receiving a consensus “Moderate Buy” rating and an average price target of $29.09.
• Elanco exceeded quarterly expectations, reporting $0.34 in EPS versus the $0.27 estimate and revenue of $1.37 billion, up 10.2% year over year. Two directors also bought a combined 50,000 shares in August.

Alyeska Investment Group L.P. purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 1,498,380 shares of the company's stock, valued at approximately $36,875,000. Alyeska Investment Group L.P. owned about 0.30% of Elanco Animal Health as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. boosted its stake in Elanco Animal Health by 14.7% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 10,953 shares of the company's stock valued at $270,000 after purchasing an additional 1,405 shares during the last quarter. Hsbc Holdings PLC increased its holdings in Elanco Animal Health by 54.0% in the 2nd quarter. Hsbc Holdings PLC now owns 62,590 shares of the company's stock worth $1,540,000 after buying an additional 21,959 shares in the last quarter. Public Employees Retirement System of Ohio raised its position in Elanco Animal Health by 113.0% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 330,645 shares of the company's stock worth $8,137,000 after buying an additional 175,412 shares during the last quarter. Proficio Capital Partners LLC bought a new position in Elanco Animal Health during the 2nd quarter valued at about $260,000. Finally, Corient Private Wealth LP bought a new position in Elanco Animal Health during the 2nd quarter valued at about $8,565,000. Institutional investors own 97.48% of the company's stock.

Analyst Upgrades and Downgrades

ELAN has been the subject of several research reports. JPMorgan Chase & Co. boosted their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday, May 7th. Citigroup lifted their target price on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a "buy" rating in a research report on Thursday, May 7th. KeyCorp increased their price target on Elanco Animal Health from $29.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Piper Sandler reaffirmed an "overweight" rating on shares of Elanco Animal Health in a report on Monday, June 29th. Finally, Morgan Stanley upped their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $29.09.

Insiders Place Their Bets

In other Elanco Animal Health news, Director Paul Herendeen acquired 10,000 shares of the company's stock in a transaction dated Friday, August 7th. The stock was purchased at an average price of $23.68 per share, with a total value of $236,800.00. Following the completion of the purchase, the director directly owned 111,687 shares in the company, valued at approximately $2,644,748.16. The trade was a 9.83% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence Erik Kurzius bought 40,000 shares of the business's stock in a transaction that occurred on Thursday, August 20th. The shares were acquired at an average price of $23.40 per share, with a total value of $936,000.00. Following the transaction, the director directly owned 188,647 shares of the company's stock, valued at $4,414,339.80. This represents a 26.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 63,198 shares of company stock worth $1,473,109 in the last three months. 1.14% of the stock is owned by company insiders.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN opened at $24.16 on Monday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. Elanco Animal Health Incorporated has a 1-year low of $17.11 and a 1-year high of $27.98. The company has a market capitalization of $12.07 billion, a P/E ratio of -58.93, a P/E/G ratio of 1.44 and a beta of 1.67. The firm's 50 day simple moving average is $24.62 and its two-hundred day simple moving average is $24.00.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source